Roche Holding (RHHBY)
(Delayed Data from OTC)
$30.08 USD
-0.15 (-0.50%)
Updated Apr 17, 2024 04:00 PM ET
4-Sell of 5 4
C Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RHHBY 30.08 -0.15(-0.50%)
Will RHHBY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
Other News for RHHBY
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
Roche notes positive data from subcutaneous version of MS drug Ocrevus
TG Therapeutics: The Cloud Over Briumvi
Global company events calendar